Effect of frailty on survival after cardiac resynchronization therapy

Arch Cardiovasc Dis. 2022 Nov;115(11):610-611. doi: 10.1016/j.acvd.2022.08.002. Epub 2022 Sep 29.

Authors

Maciej Kubala¹, Yohann Bohbot², Pierre-Henri Dromzee², Alexis Hermida², Dan Rusinaru², Christophe Tribouilloy²

Affiliations

¹ Department of Cardiology, Amiens University Hospital, 80054 Amiens, France; EA 7517 MP3CV, Jules-Verne University of Picardie, 80054 Amiens, France. Electronic address: kubala.maciej@chu-amiens.fr.
² Department of Cardiology, Amiens University Hospital, 80054 Amiens, France; EA 7517 MP3CV, Jules-Verne University of Picardie, 80054 Amiens, France.

PMID: 36272965
DOI: 10.1016/j.acvd.2022.08.002

No abstract available

Publication types

Letter

MeSH terms

Cardiac Resynchronization Therapy Devices
Cardiac Resynchronization Therapy* / adverse effects
Defibrillators, Implantable*
Frailty* / diagnosis
Frailty* / therapy
Heart Failure* / diagnosis
Heart Failure* / therapy
Humans
Treatment Outcome